Literature DB >> 1716061

Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats.

M Yamaki1, E Kusano, T Tetsuka, S Takeda, S Homma, N Murayama, Y Asano.   

Abstract

One of the mechanisms by which Li evokes polyuria is thought to be impairment of arginine vasopressin (AVP)-sensitive adenylate cyclase (AdC) in cells of the renal collecting duct. To investigate how AdC is influenced by chronic administration of Li, we created nephrogenic diabetes insipidus (NDI) in rats and microdissected the medullary collecting tubule from both control and NDI rats. In the NDI group, the 10(-6) M AVP-stimulated cAMP contents failed to increase completely, and the levels were significantly lower than that of the control group (10.4 +/- 1.4 vs. 48.4 +/- 4.7 fmol/mm, P less than 0.001). Pretreatment with pertussis toxin (PT), an inhibitor of inhibitory G protein (Gi), did not affect the basal cAMP levels in both groups, although it increased AVP-stimulated cAMP production in the NDI group in a dose- and time-dependent manner. AVP-stimulated cAMP production with over 100 ng/ml PT in the NDI group reached the levels observed in the control group. Incubation with cholera toxin, an agonist of stimulatory G protein (Gs), increased the cAMP content in the two groups to almost equal levels. To exclude the possibility that prostaglandin E2 (PGE2) is involved in the cellular mechanism of Li-induced NDI, the effect of indomethacin (Indo) on PT action was examined. However, Indo (10(-5) M) did not influence either the basal or AVP-dependent cAMP contents. From these results it is suggested that Li impairs AVP-sensitive AdC not through inhibition of Gs but through activation of Gi and that PGE2 may not be involved in the cellular pathogenesis of NDI at least in the rat at the step of cAMP formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716061     DOI: 10.1152/ajprenal.1991.261.3.F505

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Molecular mechanisms in lithium-associated renal disease: a systematic review.

Authors:  Soham Rej; Shamira Pira; Victoria Marshe; André Do; Dominique Elie; Karl J Looper; Nathan Herrmann; Daniel J Müller
Journal:  Int Urol Nephrol       Date:  2016-06-29       Impact factor: 2.370

2.  Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts.

Authors:  Janet D Klein; Yanhua Wang; Mitsi A Blount; Patrick A Molina; Lauren M LaRocque; Joseph A Ruiz; Jeff M Sands
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

Review 3.  Glycogen synthase kinase-3 regulation of urinary concentrating ability.

Authors:  Reena Rao
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-09       Impact factor: 2.894

4.  GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.

Authors:  Reena Rao; Satish Patel; Chuanming Hao; James Woodgett; Raymond Harris
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

5.  Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.

Authors:  D Marples; S Christensen; E I Christensen; P D Ottosen; S Nielsen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Do not treat the numbers: lithium toxicity.

Authors:  Peter Foulser; Yasmin Abbasi; Anand Mathilakath; Ramin Nilforooshan
Journal:  BMJ Case Rep       Date:  2017-06-02

7.  Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.

Authors:  Shixin Tao; Vijayakumar R Kakade; James R Woodgett; Pankaj Pandey; Erin D Suderman; Madhumitha Rajagopal; Reena Rao
Journal:  Kidney Int       Date:  2015-01-28       Impact factor: 10.612

8.  Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.

Authors:  Jae H Sim; Nathaniel J Himmel; Sara K Redd; Fadi E Pulous; Richard T Rogers; Lauren N Black; Seongun M Hong; Tobias N von Bergen; Mitsi A Blount
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.